Open AccessImplementation Experience With Meningococcal Serogroup B Vaccines in the United States
Author(s) -
Jaime Fergie,
Ashley Howard,
Liping Huang,
Amit Srivastava
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003033
Subject(s) - vaccination , meningococcal vaccine , medicine , family medicine , immunization , advisory committee , meningococcal disease , limiting , receipt , disease , political science , immunology , neisseria meningitidis , business , mechanical engineering , public administration , antigen , biology , bacteria , engineering , genetics , accounting , pathology
Meningococcal serogroup B (MenB) is the leading cause of invasive meningococcal disease among US adolescents and young adults, accounting for 62% of cases in 16-23-year-olds in 2018. Since 2015, the Advisory Committee on Immunization Practices (ACIP) has recommended vaccination of healthy adolescents against MenB based on shared clinical decision-making (previously called "Category B" or individual clinical decision-making). However, MenB vaccine coverage and series completion rates remain low. Herein we examine implementation experience of adolescent MenB vaccination in the United States under this nonroutine ACIP recommendation.